Abstract
Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.
Original language | English (US) |
---|---|
Pages (from-to) | 755-765 |
Number of pages | 11 |
Journal | Future Oncology |
Volume | 13 |
Issue number | 8 |
DOIs | |
State | Published - Apr 2017 |
Externally published | Yes |
Keywords
- cabozantinib
- genitourinary malignancies
- renal cell carcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research